Equities

Oncosil Medical Ltd

Oncosil Medical Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (AUD)0.007
  • Today's Change0.00 / 0.00%
  • Shares traded2.52m
  • 1 Year change-7.41%
  • Beta1.4563
Data delayed at least 20 minutes, as of Nov 22 2024 05:10 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

OncoSil Medical Ltd is an Australia-based medical device company focused on localized treatments for patients with unresectable locally advanced pancreatic cancer (LAPC). The Company is focused on the development and commercialization of its lead product candidate, the OncoSil localized radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma. The Company has developed a cancer treatment device, the OncoSil brachytherapy device, which is a critical component of a brachytherapy treatment for locally advanced unresectable pancreatic cancer. The OncoSil device delivers a targeted intratumoral placement of Phosphorous-32 (32P) in the treatment of locally advanced unresectable pancreatic cancer. The OncoSil device has received a device designation in the European Union, United Kingdom and United States for the treatment of locally advanced unresectable pancreatic cancer in combination with chemotherapy.

  • Revenue in AUD (TTM)583.20k
  • Net income in AUD-11.91m
  • Incorporated2005
  • Employees2.00
  • Location
    Oncosil Medical LtdLevel 57 Eden Park Drive, Macquarie ParkMACQUARIE 2113AustraliaAUS
  • Phone+61 28935-9629
  • Fax+61 29221-8535
  • Websitehttp://www.oncosil.com.au/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
TrivarX Ltd893.31k-1.43m6.86m4.00--0.6211--7.67-0.0045-0.00450.00270.02420.0935-------15.02-37.57-17.67-43.65100.0092.56-160.59-446.23---105.740.0016---6.99-26.3953.28--17.61--
Epsilon Healthcare Ltd7.21m-5.93m7.21m----0.7868--0.9994-0.0198-0.01980.02410.03050.383917.942.73---31.54-35.68-46.30-41.1137.9926.88-82.17-197.560.5237-9.280.2329--29.3630.99-43.77--8.14--
Firebrick Pharma Ltd14.52k-1.18m10.93m----4.33--752.45-0.0066-0.00660.000080.0120.0054--0.0267---43.64-98.70-51.22-109.33-156.89---8,098.28-80,697.286.36--0.00--1,649.40--82.71------
Anatara Lifesciences Ltd0.00-1.45m11.19m----8.12-----0.0098-0.00980.000.00710.00-------93.91-76.37-126.61-88.90------------0.00------28.27------
Argent BioPharma Ltd891.08k-17.53m12.48m--------14.01-0.5116-0.51160.0241-0.11380.08580.61441.77---168.97-129.61---254.2822.86-27.15-1,969.34-667.990.1532-37.54-----73.706.3115.81---17.96--
Acrux Ltd8.10m-5.80m13.37m43.00--4.08--1.65-0.02-0.020.0280.01130.728--2.61---52.14-45.05-71.89-54.0451.14---71.62-114.01----0.5307---32.118.91-659.16---6.20--
Althea Group Holdings Ltd30.37m-32.06m16.21m----51.78--0.5338-0.0858-0.08580.08080.00080.84382.347.03---89.06-37.78-167.97-47.1360.7053.83-105.54-94.470.4086-4.080.9466--20.8799.01-133.57---25.27--
Immuron Ltd4.90m-6.94m17.19m6.00--1.35--3.51-0.0304-0.03040.02150.05570.26121.295.43---36.96-27.01-42.53-29.3368.0674.23-141.49-245.534.87-3.030.0032--171.6715.48-83.20---37.22--
Calmer Co International Ltd4.26m-3.73m17.64m--------4.14-0.0035-0.00350.0038-0.00031.132.019.14---98.45-119.20-395.42-195.4949.6239.01-87.42-219.690.5607-12.301.27--138.9287.7928.91---20.42--
Nyrada Inc3.40m-1.39m22.01m----3.79--6.47-0.0081-0.00810.02090.02770.6147-------25.13-53.28-29.75-62.52-----40.89-236.15----0.00--115.5546.4282.12------
Oncosil Medical Ltd583.20k-11.91m31.32m2.00--4.92--53.70-0.0054-0.00540.00030.00140.0641--3.12---130.97-67.66-162.31-77.45-158.87---2,042.81-768.23----0.0147--35.54-31.37-5.03--67.76--
Little Green Pharma Ltd25.63m-8.15m39.37m----0.505--1.54-0.0272-0.02720.08560.25740.27721.0512.29---8.82---9.74--53.18---31.81--1.39-18.900.0624--29.07--4.72------
Next Science Ltd35.84m-20.76m41.63m----3.82--1.16-0.0773-0.07730.13150.03731.975.348.04---113.88-74.40-168.92-90.3178.8376.98-57.93-128.261.96--0.1045--89.3650.80-28.29---2.28--
Data as of Nov 22 2024. Currency figures normalised to Oncosil Medical Ltd's reporting currency: Australian Dollar AUD

Institutional shareholders

24.35%Per cent of shares held by top holders
HolderShares% Held
Washington H. Soul Pattinson & Co. Ltd. (Invt Mgmt)as of 01 Nov 2024535.71m14.16%
Pengana Capital Ltd.as of 26 Jul 2024385.71m10.19%
Data from 28 Jun 2024 - 01 Nov 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.